Compare Cassava Sciences Inc (FLNA) vs Micron Technology, Inc. (MU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Micron Technology, Inc. — how do they compare? Cassava Sciences Inc trades at $0.82 (market cap $39.40M), while Micron Technology, Inc. trades at $1,029 (market cap $1.17T). The key difference: Micron Technology, Inc. is far larger — about 29695.4× Cassava Sciences Inc's market cap, and Micron Technology, Inc. pays a 0.06% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cassava Sciences Inc for 37 Days and Micron Technology, Inc. for 48 Days on average.
| FLNA | MU | |
|---|---|---|
Market Cap | $39.40M | $1.17T |
Volume | 759,018 | 29,425,906 |
Sector | Health | Technology |
52-Week High | $4.64 | $1.21K |
52-Week Low | $0.68 | $181.60 |
Typical Hold Time | 37 Days | 48 Days |
Enterprise Value | -$43.28M | $1.13T |
Dividend Yield | — | 0.06% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $0.8136, down 0.26% with a bearish technical signal. The company shows negative profitability with ROE at -55.79% and ROA at -35.34%, though it has beaten EPS estimates for three consecutive quarters. Recent positive FDA news regarding the clinical hold lift on simufilam for epilepsy research provides a potential catalyst. Cash flow remains negative with net cash flow of -$33.07M in 2025.
The outlook is mixed with strong analyst support (66.7% buy ratings) against fundamental challenges. Investment opportunity lies in clinical trial success, while risks include sustained cash burn and execution hurdles. The stock's low EV/EBITDA of 1.03 and P/B of 0.62 suggest undervaluation if pipeline milestones are met.
Micron Technology (MU) trades at $1,035.84, down 4.79% today, but maintains strong bullish momentum with 500% gains over the past year. The stock shows robust fundamentals with Q2 2026 EPS beating expectations at $33.42 versus $31.77, and maintains impressive profitability with 63.8% net income margin. Technical indicators remain bullish overall despite recent pullback, with support at $1,020 and resistance at $1,064. The company's strategic customer agreements covering 35% of revenue through 2030 provide visibility into future growth.
Micron presents compelling investment potential driven by AI memory demand surge and strong financial performance, though risks include cyclical industry exposure and potential growth deceleration. Analyst consensus remains strongly bullish with 82.9% buy ratings and $1,590 price target, representing 53% upside. The stock's valuation at 13.94 P/E appears reasonable given projected revenue growth to $133.2B in 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Micron Technology, Inc.
Micron historically focused on designing and manufacturing DRAM for PCs. The firm then expanded into the NAND flash memory market. It increased its DRAM scale with the purchase of Elpida (completed in mid-2013) and Inotera (completed in December 2016). The firm's DRAM and NAND products tailored to PCs, data centers, smartphones, game consoles, automotives, and other computing devices.
Read more on MU →
